Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection

[1]  Ramon Arens,et al.  Cytomegalovirus infection and progressive differentiation of effector-memory T cells , 2018, F1000Research.

[2]  D. Hanahan,et al.  Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice , 2018, Cancer Immunology Research.

[3]  S. Verbeek,et al.  FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines , 2018, Oncotarget.

[4]  F. Salazar-Onfray,et al.  Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma , 2018, Oncoimmunology.

[5]  Daniel E. Zak,et al.  Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine , 2018, Nature Medicine.

[6]  Suzanne P. M. Welten,et al.  The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose , 2018, Front. Immunol..

[7]  D. Busch,et al.  Cytomegalovirus vector expressing RAE‐1γ induces enhanced anti‐tumor capacity of murine CD8+ T cells , 2017, European journal of immunology.

[8]  Susan E. Murray,et al.  Fibroblast-adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans , 2017, The Journal of experimental medicine.

[9]  B. Graham,et al.  Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung , 2016, Mucosal Immunology.

[10]  Jennifer D. Oduro,et al.  Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors , 2016, PLoS pathogens.

[11]  P. Klenerman,et al.  Cytomegalovirus Reinfections Stimulate CD8 T-Memory Inflation , 2016, PloS one.

[12]  R. Arens,et al.  Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination , 2016, Front. Immunol..

[13]  C. Daskalakis,et al.  Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  P. Klenerman,et al.  T cell responses to cytomegalovirus , 2016, Nature Reviews Immunology.

[15]  C. Melief,et al.  Vaccines for established cancer: overcoming the challenges posed by immune evasion , 2016, Nature Reviews Cancer.

[16]  R. Roden,et al.  Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease , 2016, Cell & Bioscience.

[17]  Suzanne P. M. Welten,et al.  Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity , 2016, Journal of Virology.

[18]  Ramon Arens,et al.  In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity , 2016, Immunity.

[19]  H. Feldmann,et al.  Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection , 2016, Scientific Reports.

[20]  B. Korber,et al.  Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E , 2016, Science.

[21]  S. H. van der Burg,et al.  Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response , 2016, Clinical Cancer Research.

[22]  Jennifer D. Oduro,et al.  Murine cytomegalovirus (CMV) infection via the intranasal route offers a robust model of immunity upon mucosal CMV infection. , 2016, The Journal of general virology.

[23]  Suzanne P. M. Welten,et al.  The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells , 2015, The Journal of Immunology.

[24]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[25]  H. Smilowitz,et al.  Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8+ T-cell Response and Protects Mice from Melanoma , 2015, Cancer Immunology Research.

[26]  P. Klenerman,et al.  A Novel Murine Cytomegalovirus Vaccine Vector Protects against Mycobacterium tuberculosis , 2014, The Journal of Immunology.

[27]  Suzanne P. M. Welten,et al.  Viral inoculum dose impacts memory T‐cell inflation , 2014, European journal of immunology.

[28]  J. Haefliger,et al.  Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder. , 2014, The Journal of urology.

[29]  Finn E. Grey,et al.  Cytomegalovirus-based cancer vaccines expressing TRP2 induce rejection of melanoma in mice. , 2013, Biochemical and biophysical research communications.

[30]  T. Wu,et al.  Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects , 2013, Cancer Immunology, Immunotherapy.

[31]  Suzanne P. M. Welten,et al.  CD27-CD70 Costimulation Controls T Cell Immunity during Acute and Persistent Cytomegalovirus Infection , 2013, Journal of Virology.

[32]  L. Čičin-Šain,et al.  The Context of Gene Expression Defines the Immunodominance Hierarchy of Cytomegalovirus Antigens , 2013, The Journal of Immunology.

[33]  C. Melief,et al.  Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors , 2012, The Journal of Immunology.

[34]  P. Caposio,et al.  A Cytomegalovirus-based Vaccine Expressing a Single Tumor-specific CD8+ T-cell Epitope Delays Tumor Growth in a Murine Model of Prostate Cancer , 2012, Journal of immunotherapy.

[35]  P. Klenerman,et al.  Memory T cell inflation: understanding cause and effect. , 2012, Trends in immunology.

[36]  H. Feldmann,et al.  A Replicating Cytomegalovirus-Based Vaccine Encoding a Single Ebola Virus Nucleoprotein CTL Epitope Confers Protection against Ebola Virus , 2011, PLoS neglected tropical diseases.

[37]  P. Klenerman,et al.  Differential B7–CD28 Costimulatory Requirements for Stable and Inflationary Mouse Cytomegalovirus-Specific Memory CD8 T Cell Populations , 2011, The Journal of Immunology.

[38]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[39]  Anthony R. Fehr,et al.  The Human Cytomegalovirus Gene UL79 Is Required for the Accumulation of Late Viral Transcripts , 2011, Journal of Virology.

[40]  M. Smyth,et al.  Innate immunity defines the capacity of antiviral T cells to limit persistent infection , 2010, The Journal of experimental medicine.

[41]  E. Puchhammer-Stöckl,et al.  Human cytomegalovirus (HCMV) genotype populations in immunocompetent individuals during primary HCMV infection. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[42]  L. Picker,et al.  Evasion of CD8+ T Cells Is Critical for Superinfection by Cytomegalovirus , 2010, Science.

[43]  W. Britt,et al.  Cytomegalovirus reinfections in healthy seroimmune women. , 2010, The Journal of infectious diseases.

[44]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[45]  L. Picker,et al.  Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge , 2009, Nature Medicine.

[46]  Rustom Antia,et al.  Memory CD8 T-cell compartment grows in size with immunological experience , 2009, Nature.

[47]  Lyric C. Bartholomay,et al.  Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria , 2008, Proceedings of the National Academy of Sciences.

[48]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  M. Cannon,et al.  Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection , 2007, Reviews in medical virology.

[50]  M. Messerle,et al.  Use of Bacterial Artificial Chromosomes in Generating Targeted Mutations in Human and Mouse Cytomegaloviruses , 2007, Current protocols in immunology.

[51]  E. Remmerswaal,et al.  Differential Usage of Cellular Niches by Cytomegalovirus versus EBV- and Influenza Virus-Specific CD8+ T Cells , 2006, The Journal of Immunology.

[52]  Qiyi Tang,et al.  Mouse Cytomegalovirus Crosses the Species Barrier with Help from a Few Human Cytomegalovirus Proteins , 2006, Journal of Virology.

[53]  Louis J. Picker,et al.  Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects , 2005, The Journal of experimental medicine.

[54]  Nancy A. Jenkins,et al.  Simple and highly efficient BAC recombineering using galK selection , 2005, Nucleic acids research.

[55]  S. H. van der Burg,et al.  Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  S. Dewhurst,et al.  Murine Cytomegalovirus Abortively Infects Human Dendritic Cells, Leading to Expression and Presentation of Virally Vectored Genes , 2003, Journal of Virology.

[57]  P. Klenerman,et al.  Regulation of the Class II MHC Pathway in Primary Human Monocytes by Granulocyte-Macrophage Colony-Stimulating Factor 1 , 2003, The Journal of Immunology.

[58]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[59]  S. H. van der Burg,et al.  Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. , 2001, Vaccine.

[60]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[61]  J. Bale,et al.  Cytomegalovirus reinfection in young children. , 1996, The Journal of pediatrics.

[62]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[63]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.